Advancements in Lymphoma Treatment Strategies

This chapter explores the evolution of lymphoma treatments, focusing on the role of rituximab, lenalidomide, and obinutuzumab, alongside the significance of genetic markers in therapy choices. It highlights the emerging use of bispecific antibodies and CAR-T therapies, discussing their dosing regimens, efficacy, and safety profiles, particularly concerning cytokine release syndrome. The chapter concludes with a comparative analysis of innovative treatments and their feasibility for patient care in community settings.